Alogliptin

Alogliptin

• CAS Number: 850649-61-5
• UNSPSC Description: Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of DPP-4 with an IC50 of [1][2][3].
• Target Antigen: Dipeptidyl Peptidase; Ferroptosis
• Type: Reference compound
• Related Pathways: Apoptosis;Metabolic Enzyme/Protease
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/alogliptin.html
• Purity: 99.92
• Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : 10 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: O=C(C=C(N1C[C@H](N)CCC1)N(C2=O)CC3=C(C#N)C=CC=C3)N2C
• Molecular Weight: 339.399
• References & Citations: [1]Feng J, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50(10):2297-300.|[2]Ta NN, et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec;213(2):429-35.|[3]Asakawa T, et al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci. 2009 Jul 17;85(3-4):122-6.|[4]Moritoh Y, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol. 2009 Jan 14;602(2-3):448-54.|[5]Hao FL, et, al. The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells. Biomed Pharmacother. 2019 Jan;109:181-187.Sci Rep. 2019 Dec 2;9(1):18094.|Sci Signal. 2023 Jan 17;16(768):eabh1083.|Biochem Biophys Res Commun. 2019 Apr 2;511(2):387-393. |Biol Chem. 2023 Jan 12.|Chromatography. 2015,36(1):19-24.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched